European Journal of Nuclear Medicine

, Volume 24, Issue 1, pp 68–71

Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease

  • J. Booij
  • G. Tissingh
  • A. Winogrodzka
  • G. J. Boer
  • J. C. Stoof
  • E. C. Wolters
  • E. A. van Royen
Short communication

DOI: 10.1007/BF01728311

Cite this article as:
Booij, J., Tissingh, G., Winogrodzka, A. et al. Eur J Nucl Med (1997) 24: 68. doi:10.1007/BF01728311

Abstract

Loss of striatal dopamine (DA) transporters in Parkinson's disease (PD) has been accurately assessed in vivo by single-photon emission tomography (SPET) studies using [123I]β-CIT. However, these studies have also shown that adequate imaging of the striatal DA transporter content can be performed only 20–30 h following the injection of [123I]β-CIT, which is not convenient for routine out-patient evaluations. Recently, a new ligand,N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)tropane (FP-CIT), became available for in vivo imaging of the DA transporter. The faster kinetics of [123I]FP-CIT have been shown to allow adequate acquisition as early as 3 h following injection. In the present study, loss of striatal DA transporters in five non-medicated PD patients was assessed on two consecutive SPET scans, one with [123I]β-CIT (24 h following injection) and one with [123I]FP-CIT (3 h following injection). The ratios of specific to non-specific [123I]FP-CIT uptake in the caudate nucleus and putamen were consistently 2.5-fold lower than those of [123I]β-CIT. However, when the uptake ratio of both ligands in these brain regions of patients was expressed as a percentage of the uptake ratio found in healthy controls, both the decrease and the variation of the data were similar. It is concluded on the basis of these findings that [123I]FP-CIT seems as good as [123I]β-CIT for the assessment of the dopaminergic deficit in PD. The faster kinetics of [123I]FP-CIT are a clear advantage.

Key words

Parkinson's diseaseSingle-photon emission tomographyDopamine transporter imagingCocaine analogues

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • J. Booij
    • 1
  • G. Tissingh
    • 2
  • A. Winogrodzka
    • 2
  • G. J. Boer
    • 3
  • J. C. Stoof
    • 2
  • E. C. Wolters
    • 2
  • E. A. van Royen
    • 1
  1. 1.Department of Nuclear Medicine, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  2. 2.Department of Neurology, Research Institute NeurosciencesVrije UniversiteitThe Netherlands
  3. 3.Netherlands Institute for Brain ResearchThe Netherlands